Ultherapy

What it is

Ultherapy (the Ulthera System) is a non-invasive aesthetic medical device that delivers microfocused ultrasound energy at three precisely calibrated tissue depths via an articulated transducer handpiece. Its defining feature is real-time ultrasound visualization, which enables the treating physician to see underlying tissue architecture to a depth of 8 mm before and during energy delivery. This visualization is the differentiator versus other HIFU devices.

The platform reached over 3 million procedures performed worldwide as of January 2025. In Korean clinical practice, 울쎄라 is the canonical FDA-cleared lifting reference point against which Korean alternatives such as 슈링크 (Shurink Universe) are benchmarked.

How it works

The mechanism operates in two phases. First, the ultrasound beam is focused to raise focal tissue temperature to approximately 60 to 70 degrees Celsius within milliseconds, creating discrete thermal coagulation points (TCPs) where collagen fibers undergo denaturation and immediate physical contraction. Second, TCPs trigger a wound-healing response: macrophage infiltration by Day 14, HSP47-positive fibroblast recruitment, and by Day 90 newly synthesized collagen and elastin populate the TCP sites.

A 2024 Journal of Cosmetic Dermatology histological study confirmed neoelastogenesis alongside neocollagenesis as a mechanism of MFU-V action. The energy-tissue interaction is purely thermal. Depth selectivity is achieved geometrically through transducer focal-zone engineering rather than chromophore targeting.

Origin and development

Ulthera, Inc. (Mesa, Arizona) was acquired by Merz Pharma Group in July 2014 for approximately USD 600 million. The device received its first FDA clearance on September 29, 2009 via De Novo pathway for non-invasive brow lift, a second clearance in October 2012 for lifting lax submental and neck tissue, and a third in June 2014 for improvement of décolletage lines. Korea's initial MFDS approval was obtained in 2009, coinciding with US clearance.

The next-generation Ultherapy PRIME platform received FDA 510(k) K243035 in February 2025 and MFDS approval in January 2025.

Regulatory status

Jurisdiction	Status	Notes
Korea (MFDS)	Approved (2009); PRIME (2025)	Medical device (의료기기); 집속형초음파자극시스템 (focused ultrasound stimulator system). Ultherapy PRIME granted approval January 2025
United States (FDA)	Cleared for specific anatomical indications	De Novo clearance 2009 (brow lift); 510(k) K132028 (neck/submental, 2012); K134032 (décolletage, 2014); K243035 (PRIME, 2025). Class II, Product Code OHV, 21 CFR 878.4590. Full-face use, common in practice, is off-label in the United States
European Union (CE)	CE-marked	Marketed throughout the EU under the Merz Aesthetics brand

Typical protocol

Frequency: 1 session, with maintenance at 12 to 18 months
Korean clinic packaging: typically priced by shot count (샷수). 300-shot partial and 600-shot full-face are the most common packages
Session duration: approximately 60 to 90 minutes for full-face plus neck
Anesthesia: topical lidocaine 4 to 5 percent applied 30 to 60 minutes prior. Some Korean clinics add IV analgesic supplementation (통증수액)
Transducer depths: 1.5 mm (10 MHz) for superficial dermis, 3.0 mm (7 MHz) for deep dermis, 4.5 mm (4 or 7 MHz) for SMAS
Downtime: minimal. Mild erythema and edema typically resolve within hours to a few days

Commonly reported effects

Intended effects include lifting of the brow, jowls, and neck, reduction of submental laxity, improvement in décolletage wrinkles, and secondary improvements in skin quality.

Documented adverse events include the following. Marginal mandibular nerve paresis is rare but documented, attributed to proximity of the nerve to the SMAS layer targeted by the 4.5 mm transducer in the mandibular region. Reported cases were generally transient. A 2025 systematic review of FDA MAUDE database records and peer-reviewed literature identified neurologic sequelae (nerve damage, focal numbness, dysesthesia, ptosis) and subcutaneous fat atrophy from inadvertent thermal injury to facial fat pads as the most frequently reported serious adverse events in post-market surveillance.

The published evidence base supports efficacy with a favorable safety profile when treatment is delivered with appropriate operator anatomical knowledge.

Korea vs US availability

Per 모두닥 (Modoodoc) 2026 platform data, full-face Ultherapy in Seoul ranges from approximately ₩1,000,000 to ₩2,000,000. In the United States, full face and neck treatment typically runs $3,000 to $5,500 per session.

Korean pricing represents approximately 40 to 60 percent of US equivalent pricing at standard clinic rates, and as low as 30 percent during promotional periods. Counterfeit transducer-tip risk is documented in Korea: Korean courts sentenced vendors to 4 to 12 months imprisonment in 2019 under the Medical Device Act for selling illegally modified Ultherapy transducer tips. Verifying tip authenticity is meaningful at the appointment.

What to research before

Verify tip authenticity. Counterfeit Ultherapy transducer tips have been prosecuted in Korea. Ask to see the original packaging at the appointment and confirm the tip is genuine.
Confirm shot count and transducer depths up front. Pricing scales with shot count. A 300-shot session is materially different from a 600-shot session. Ask which transducer depths will be used and how many shots per depth.
Ultherapy vs Shurink Universe. Both are HIFU. Ultherapy has FDA clearance for facial lifting; Shurink Universe does not but is a Korean-developed alternative. Make sure the clinic is using the device they advertised.
Verify operator credentials. SMAS-depth ultrasound requires anatomical knowledge of facial nerve pathways. Our credential verification guide covers KSPRS and dermatology specialty registries.
See also: our Korean Surgery Safety Guide.

Related procedures

Shurink (Ultraformer MPT) — Korean HIFU alternative, MFDS-approved, not FDA-cleared for facial lifting
Thermage — radiofrequency-based skin tightening, complementary mechanism
Thread lifts — mechanical lifting via PDO/PLLA/PCL filaments
Facelift surgery — surgical SMAS repositioning when non-invasive lift is insufficient

Sources

BioSpace. Ulthera Receives First-Ever FDA Clearance. September 16, 2009. https://www.biospace.com/ulthera-receives-first-ever-fda-clearance-to-market-ultrasound-technology-for-facial-aesthetic-improvement
이엠디 (EMD Korea). 초음파 리프팅 기기 울쎄라, 전세계 300만회 시술 돌파. January 20, 2025. https://mdon.co.kr/mobile/article.html?no=34029
Couture-Trudeau L et al. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin. J Cosmet Dermatol. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11743342/
Merz Canada. Merz Finalizes Acquisition of Ulthera, Inc. July 2014. https://www.merzcanada.com/files/merz-announces-closing-of-ulthera-acquisition.pdf
메디포뉴스 (Medifonews). 멀츠 에스테틱스 코리아, 울쎄라피 프라임 국내 허가 획득. February 18, 2025. https://medifonews.com/news/article.html?no=199811
Park JY et al. Treatment Protocol on Using Microfocused Ultrasound with Visualization for Skin Quality Improvement: The Korean Experience. Plast Reconstr Surg Glob Open. 2023;11(5):e5049. https://pmc.ncbi.nlm.nih.gov/articles/PMC10219723/
Hitchcock TM, Dobke MK. Review of the Safety Profile for MFU-V. J Cosmet Dermatol. 2014;13(4):329–335. https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.12111
Systematic Review. Microfocused Ultrasound With Visualization: A Systematic Review of Adverse Events. Dermatol Surg. 2025;51(4):424–429. https://pubmed.ncbi.nlm.nih.gov/39625163/
모두닥 (Modoodoc). 울쎄라 가격정보 2026. https://www.modoodoc.com/blog/price-detail
메디칼타임즈 (Medical Times Korea). 울쎄라 팁 불법 개·변조 업자 징역형. October 15, 2019. https://www.medicaltimes.com/Mobile/News/NewsView.html?ID=1129538
ASPS 2023 Cosmetic Procedures Average Cost. https://www.plasticsurgery.org/Documents/News/Statistics/2023/cosmetic-procedures-average-cost-2023.pdf